See how Medable is shaping the decentralized clinical products industry to drive trial efficiencies, accelerate science and enable faster cures for every body and every biology.
Why Medable stands out from other decentralized trial product competitors:
- DCT system that effortlessly scales and integrated with any eClinical platform
- Comprehensive suite of decentralized product capabilities
- Flexible and extensible platform that supports DCT workflows
- Superior customer experience with a strong escalation pathway
Medable is making trials accessible for everyone everywhere – and enabling effective therapies to reach patients faster. Medable platform has been deployed in over 150 decentralized and hybrid trials for 1M+ patients, and supports 60+ countries and 60+ languages on its platform. By minimizing the need for in-person site visits, Medable customers have achieved unprecedented results – including 3X faster enrollment, 90 percent retention rates, and 50 percent cost reductions
Assessments for Covance, Delve Health, eClinicalHealth, ERT, and Signant Health excludes product vendor inputs and are based on Everest Group’s proprietary Transaction Intelligence (TI) database, product vendor public disclosures, and Everest Group’s interactions with decentralized clinical trial product buyers.Analysis for Signant Health is based on capabilities after its acquisition of Virtual, analysis for ERT is based on capabilities after its merger with BioClinica, and analysis for Covance is based capabilities after its acquisition with SnaploT. Source: Everest Group (2021). This assessment has been licensed to Medable.